Chemotherapy-Sparing Strategy Shows Promise for Rare Lymphoma
A Phase 2 trial found that CAPA followed by radiotherapy achieved high response rates and promising survival outcomes in early-stage NKTCL, with low rates of severe neutropenia and anaemia.







